TP53 and lung adenocarcinoma: Several TP53-deficient tumors, including colon, head and neck, liver, lung adenocarcinoma and stomach cancers showed lower expression levels of RNF144B in comparison to TP53-proficient tumour samples, however this association only reached statistical significance in colon and stomach cancer datasets (Fig. 1B).